Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.
In patients with human immunodeficiency virus (HIV) infections or the acquired immunodeficiency syndrome (AIDS), zidovudine is a first-line therapy that reduces morbidity and may reduce mortality.  By delaying progression to AIDS, the drug reduces the duration and incidence of hospitalisations in a given time period, resulting in overall decreases in the cost of medical treatment per unit of survival time.  In current therapeutic dosages zidovudine is generally well tolerated.  Most pharmacoeconomic and quality-of-life studies of this agent were conducted using data relating to higher dosages and higher drug acquisition costs than those currently applicable, but nevertheless generally support the cost-effectiveness of zidovudine in patients with HIV disease.  Studies examining the use of the drug in higher dosages demonstrate neither clear positive nor negative effects of the drug on quality of life. The cost effectiveness of the drug as prophylaxis against seroconversion after occupational exposure to HIV is dependent primarily on the establishment of clinical effectiveness in this condition.  Further pharmacoeconomic studies should examine changes to dosage and cost factors, along with direct nonmedical treatment costs, indirect medical treatment costs and the effects of the drug on quality of life.  An evaluation of existing studies suggests that if these factors were accounted for, zidovudine might be shown to be more clearly cost effective, and indeed its use in the treatment of patients with HIV disease might be found to result in cost savings.
Langtry
H D
HD
Adis International Limited, Auckland, New Zealand.
Palmer
K J
KJ
Benfield
P
P
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology / Q000503:physiopathology; D000293:Adolescent; D000328:Adult; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D004361:Drug Tolerance; D017850:Economics, Pharmaceutical; D005069:Evaluation Studies as Topic; D005260:Female; D005569:Formularies as Topic; D006678:HIV; D015658:HIV Infections / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology / Q000503:physiopathology; D017048:Health Care Costs; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D017059:Models, Econometric; D016273:Occupational Exposure; D011247:Pregnancy; D011788:Quality of Life; D015996:Survival Rate; D015215:Zidovudine / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use*